Trans-Arterial Radioembolization with Yttrium-90 of Unresectable and Systemic Chemotherapy Resistant Hepatoblastoma in Three Toddlers

Creative Commons License

Ballı H. T., Aikimbaev K., Güney İ. B., Pişkin F. C., Yagci-Kupeli B., Küpeli S., ...Daha Fazla

CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, cilt.45, ss.344-348, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1007/s00270-021-03026-6
  • Dergi Adı: CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Agricultural & Environmental Science Database, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.344-348
  • Anahtar Kelimeler: Hepatoblastoma Toddlers Transarterial Radioembolization Yttrium-90, PRIMARY HEPATIC MALIGNANCIES, SURGICAL RESECTION, CHEMOEMBOLIZATION, LIVER
  • Çukurova Üniversitesi Adresli: Evet

Özet

The aim of this short communication was to report the results of transarterial radioembolization (TARE) with Yttrium-90 (Y90) loaded resin microspheres in three toddlers with unresectable and systemic chemotherapy-resistant HB hepatoblastoma (HB). Six TARE procedures were performed on the patients. The dose required for treatment was calculated using partition model. Administered doses of Y90 were 1.369, 0.851, and 1.147 GBq. Complete radiological response in two patients and partial response enabling liver resection in one patient were achieved. Neither life-threatening nor minor complications developed after the treatment. These results demonstrates that HB is a radiosensitive neoplasm, and TARE-Y90 can be used as the primary, neoadjuvant and palliative treatment method in patients with unresectable and systemic chemotherapy-resistant HBs. However, studies with higher number of patients and long-term results are required.